Targeting NCCA-ATP channel for organ protection following ischemic episode
US9511075B2 · kind B2 · utility
3Cited by
38References
25Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Jan 11, 2008 |
| Grant date | Dec 6, 2016 |
| Priority date | — |
| Expiry date | Dec 26, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns protection of an organ or tissue following an ischemic episode In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1 Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.